# The Case of "Triple" Versus "Double" Therapy for Patients With High Volume Metastatic Hormone Sensitive Prostate Cancer

> **NCT06446401** · — · RECRUITING · sponsor: **Uppsala University** · enrollment: 1400 (estimated)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** ADT + NHT + Docetaxel
- **DRUG:** ADT + NHT

## Key facts

- **NCT ID:** NCT06446401
- **Lead sponsor:** Uppsala University
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2024-10-20
- **Primary completion:** 2026-12-31
- **Final completion:** 2031-12-31
- **Target enrollment:** 1400 (ESTIMATED)
- **Last updated:** 2025-03-04

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06446401

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06446401, "The Case of "Triple" Versus "Double" Therapy for Patients With High Volume Metastatic Hormone Sensitive Prostate Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06446401. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*